Dendrite Collaborates with Microsoft to Create Next Generation Solutions for Life Sciences
November 13 2006 - 8:00AM
Business Wire
Dendrite International, Inc. (NASDAQ:DRTE), a leading provider of
pharmaceutical industry solutions, today announced a strategic
relationship with Microsoft Corp. (NASDAQ: MSFT) aimed at
developing new Dendrite solutions on the Microsoft software
platform. Dendrite�s pharmaceutical expertise � coupled with
Microsoft�s technologies in business intelligence (BI) and
performance management � will produce solutions to enable
pharmaceutical companies to reach prescribers and patients more
effectively. Dendrite will develop its solutions on a range of
Microsoft products, including Microsoft SQL Server 2005, Windows
Vista and Windows Mobile. As part of this relationship, Dendrite
will also participate in Microsoft�s Technology Adoption Program
(TAP) which seeks to obtain real-world customer feedback on
Microsoft pre-release products. In turn, Microsoft will work
closely with Dendrite�s R&D efforts to enable faster
development cycles of life science-specific solutions that give
companies a competitive advantage. �As the global pharmaceutical
industry continues to rapidly evolve, it creates a unique set of
circumstances that require companies to respond quickly, reliably
and efficiently,� said Subhash Vaid, Dendrite vice president of
product marketing. �We�re optimistic that Dendrite�s vast
pharmaceutical industry experience and Microsoft�s strength in
technology will lead to the creation of a whole new set of rich
solutions that will cater to these needs.� �Pharmaceutical
companies are faced with the need to communicate directly to
consumers as well as physicians in new ways, while adding savings
to the bottom line,� said Paul Mattes, industry solutions director,
U.S. Pharmaceutical and Life Sciences Vertical Group, Microsoft.
�This expanded relationship will allow companies to benefit from
Dendrite�s pharmaceutical expertise, while leveraging their
existing IT investments with Microsoft�s familiar and easy-to-use
technology.� Dendrite�s strategic decision in July to make its
flagship sales force effectiveness solution Mobile IntelligenceTM
available on Microsoft SQL Server 2005 was a first step in the
relationship aimed at providing life science customers with
additional options that could result in a lower total cost of
ownership. As a result of this collaboration, the first application
is expected to be available during the first quarter of 2007 in the
United States and Japan. About Dendrite Founded in 1986, Dendrite
International (NASDAQ: DRTE) enables sales, marketing, clinical and
compliance solutions for the global pharmaceutical industry. The
Company�s clients are located in more than 50 countries and include
the world's top 20 pharmaceutical companies. Note: Dendrite is a
registered trademark of Dendrite International, Inc. This document
may contain forward-looking statements that may be identified by
such forward-looking terminology as "expect," "believe,"
"anticipate," "will," "intend," "plan," "target," "outlook,"
"guidance," and similar statements or variations. Such
forward-looking statements are based on our current expectations,
estimates, assumptions and projections and involve significant
risks and uncertainties, including risks which may result from our
dependence on the pharmaceutical industry; fluctuations in
quarterly revenues due to lengthy sales and implementation cycles
for certain of our solutions; our fixed expenses in relation to
fluctuating revenues and variations in customers' budget cycles;
dependence on certain major customers; changes in demand for our
products and services attributable to any weakness experienced in
the economy or mergers, acquisitions and consolidations in the
pharmaceutical industry; successful and timely development and
introduction of new products and versions; rapid technological
changes; increased competition; international operations;
integrating the entities we acquire; our ability to effectively
manage our growth; the protection of our proprietary technology;
our ability to compete in the Internet-related products and
services market; the continued demand for Internet-related products
and services; the ability of our third party vendors to respond to
technological change; our ability to maintain our relationships
with third-party vendors; less favorable than anticipated results
from strategic relationships; dependence of data solutions on
strategic relationships; events which may affect the U.S. and world
economies; and catastrophic events which could negatively affect
our information technology infrastructure. Other important factors
that should be reviewed and carefully considered are included in
the company's 10-K, 10-Qs, and other reports filed with the SEC.
Actual results may differ materially. The company assumes no
obligation for updating any such forward-looking statements to
reflect actual results, changes in assumptions or other changes
affecting such forward-looking statements. Dendrite International,
Inc. (NASDAQ:DRTE), a leading provider of pharmaceutical industry
solutions, today announced a strategic relationship with Microsoft
Corp. (NASDAQ: MSFT) aimed at developing new Dendrite solutions on
the Microsoft software platform. Dendrite's pharmaceutical
expertise - coupled with Microsoft's technologies in business
intelligence (BI) and performance management - will produce
solutions to enable pharmaceutical companies to reach prescribers
and patients more effectively. Dendrite will develop its solutions
on a range of Microsoft products, including Microsoft SQL Server
2005, Windows Vista and Windows Mobile. As part of this
relationship, Dendrite will also participate in Microsoft's
Technology Adoption Program (TAP) which seeks to obtain real-world
customer feedback on Microsoft pre-release products. In turn,
Microsoft will work closely with Dendrite's R&D efforts to
enable faster development cycles of life science-specific solutions
that give companies a competitive advantage. "As the global
pharmaceutical industry continues to rapidly evolve, it creates a
unique set of circumstances that require companies to respond
quickly, reliably and efficiently," said Subhash Vaid, Dendrite
vice president of product marketing. "We're optimistic that
Dendrite's vast pharmaceutical industry experience and Microsoft's
strength in technology will lead to the creation of a whole new set
of rich solutions that will cater to these needs." "Pharmaceutical
companies are faced with the need to communicate directly to
consumers as well as physicians in new ways, while adding savings
to the bottom line," said Paul Mattes, industry solutions director,
U.S. Pharmaceutical and Life Sciences Vertical Group, Microsoft.
"This expanded relationship will allow companies to benefit from
Dendrite's pharmaceutical expertise, while leveraging their
existing IT investments with Microsoft's familiar and easy-to-use
technology." Dendrite's strategic decision in July to make its
flagship sales force effectiveness solution Mobile Intelligence(TM)
available on Microsoft SQL Server 2005 was a first step in the
relationship aimed at providing life science customers with
additional options that could result in a lower total cost of
ownership. As a result of this collaboration, the first application
is expected to be available during the first quarter of 2007 in the
United States and Japan. About Dendrite Founded in 1986, Dendrite
International (NASDAQ: DRTE) enables sales, marketing, clinical and
compliance solutions for the global pharmaceutical industry. The
Company's clients are located in more than 50 countries and include
the world's top 20 pharmaceutical companies. Note: Dendrite is a
registered trademark of Dendrite International, Inc. This document
may contain forward-looking statements that may be identified by
such forward-looking terminology as "expect," "believe,"
"anticipate," "will," "intend," "plan," "target," "outlook,"
"guidance," and similar statements or variations. Such
forward-looking statements are based on our current expectations,
estimates, assumptions and projections and involve significant
risks and uncertainties, including risks which may result from our
dependence on the pharmaceutical industry; fluctuations in
quarterly revenues due to lengthy sales and implementation cycles
for certain of our solutions; our fixed expenses in relation to
fluctuating revenues and variations in customers' budget cycles;
dependence on certain major customers; changes in demand for our
products and services attributable to any weakness experienced in
the economy or mergers, acquisitions and consolidations in the
pharmaceutical industry; successful and timely development and
introduction of new products and versions; rapid technological
changes; increased competition; international operations;
integrating the entities we acquire; our ability to effectively
manage our growth; the protection of our proprietary technology;
our ability to compete in the Internet-related products and
services market; the continued demand for Internet-related products
and services; the ability of our third party vendors to respond to
technological change; our ability to maintain our relationships
with third-party vendors; less favorable than anticipated results
from strategic relationships; dependence of data solutions on
strategic relationships; events which may affect the U.S. and world
economies; and catastrophic events which could negatively affect
our information technology infrastructure. Other important factors
that should be reviewed and carefully considered are included in
the company's 10-K, 10-Qs, and other reports filed with the SEC.
Actual results may differ materially. The company assumes no
obligation for updating any such forward-looking statements to
reflect actual results, changes in assumptions or other changes
affecting such forward-looking statements.
Dendrite (NASDAQ:DRTE)
Historical Stock Chart
From Jul 2024 to Aug 2024
Dendrite (NASDAQ:DRTE)
Historical Stock Chart
From Aug 2023 to Aug 2024